Lilly withdraws chronic pain filing for Cymbalta in US
This article was originally published in Scrip
Executive Summary
Lillyhas withdrawn its sNDA from the US FDAfor its SNRI antidepressant Cymbalta (duloxetine HCl) for the management of chronic pain. Lilly plans to resubmit the application in the first half of 2009, adding data from a recently completed positive study in chronic osteoarthritis pain of the knee.